2-methyl-1-(phenylsulfonyl)pyrrole | 115027-28-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-methyl-1-(phenylsulfonyl)pyrrole
• 英文别名: 1-(phenylsulfonyl)-2-methyl-1H-pyrrole；2-methyl-1-phenylsulfonylpyrrole；1-(benzenesulfonyl)-2-methylpyrrole
• CAS: 115027-28-6
• 化学式: C₁₁H₁₁NO₂S
• 分子量: 221.28
• InChiKey: VFPQLWVMVDJINH-UHFFFAOYSA-N

物化性质

• 沸点：
  383.7±35.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(phenylsulfonyl)pyrrole 在 三氯化铝 、 溴 作用下， 以 氯仿 为溶剂， 反应 0.5h， 生成 2-bromo-1-<2-methyl-1-(phenylsulfonyl)pyrrol-4-yl>ethanone
  参考文献：
  名称：

  Antiulcer agents. 4-Substituted 2-guanidinothiazoles: reversible, competitive, and selective inhibitors of gastric H+,K+-ATPase

  摘要：

  A series of 4-substituted 2-guanidinothiazoles has been found to inhibit the gastric proton-pump enzyme H+,K(+)-ATPase. In general, these compounds were reversible inhibitors of canine gastric H+,K(+)-ATPase, competitive at the K+ site, and selective relative to canine renal Na+,K(+)-ATPase. Structure-activity relationship (SAR) studies on this series revealed no general replacement for the guanidinothiazole. On the other hand, use of pyrrolyl, phenyl, and indolyl groups as the C-4 substituent yielded active compounds. Extensive studies of substitution patterns on these 4-aryl groups led to more active compounds, but no consistent SAR became apparent. Monosubstitution of the guanidine and substitution of the thiazole at C-5 both often led to increased activity, but combining these changes generated compounds less active than the parents. Despite 100-fold improvement in in vitro inhibitory potency, only a 3-fold increase in gastric antisecretory activity in rats was observed for these agents.

  DOI：

  10.1021/jm00164a012
• 作为产物：
  描述：

  1-(苯磺酰)-2-吡咯甲醛 在 三氯化铝 、 硼烷-叔丁基胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以70%的产率得到2-methyl-1-(phenylsulfonyl)pyrrole
  参考文献：
  名称：

  Ketcha, Daniel M.; Carpenter, Kenneth P.; Atkinson, Steven T., Synthetic Communications, 1990, vol. 20, # 11, p. 1647 - 1655

  摘要：

  DOI：

文献信息

• FIBROSIS INHIBITOR
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1479384A1

  公开（公告）日：2004-11-24

  Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

  药物作为器官或组织的纤维化抑制剂而有用，包括具有以下式（I）的化合物： 其中环Z是可选择取代的吡咯环等；W2是-CO-，-SO2-，可选择取代的C1-C4烷基等；Ar2是可选择取代的芳基等；W1和Ar1表示如下（1）和（2）： （1）W1是可选择取代的C1-C4烷基等；Ar1是可选择取代的具有1至4个氮原子作为环形成原子的双环杂芳基： （2）W1是可选择取代的C2-C5烷基，可选择取代的C2-C5烯基等；以及 Ar1是芳基或单环杂芳基，其在相对于W1的结合位置的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐。
• Pyrrole derivatives
  申请人：——

  公开号：US20030181496A1

  公开（公告）日：2003-09-25

  Pyrrole derivatives represented by the following formula: 1 wherein Ring Z is an optionally substituted pyrrole ring, etc.; W 2 is —CO—, —SO 2 —, an optionally substituted C 1 -C 4 alkylene, etc.; Ar 2 is an optionally substituted aryl, etc.; W 2 and Ar 1 mean the following (1) and (2): (1) W 1 is an optionally substituted C 1 -C 4 alkylene, etc.; Ar 1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W 1 is an optionally substituted C 2 -C 5 alkylene, an optionally substituted C 2 -C 5 alkenylene, etc.; and Ar 1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W 1 , or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

  以下是用中文翻译的结果： 由以下公式表示的吡咯衍生物： 其中环Z是可选择取代的吡咯环等；W 2 是—CO—，—SO 2 —，可选择取代的C 1 -C 4 烷基等；Ar 2 是可选择取代的芳基等；W 2 和Ar 1 表示如下（1）和（2）： （1）W 1 是可选择取代的C 1 -C 4 烷基等；Ar 1 是具有1至4个氮原子作为环形成原子的可选择取代的双环杂芳基： （2）W 1 是可选择取代的C 2 -C 5 烷基，可选择取代的C 2 -C 5 烯基等；Ar 1 是芳基或单环杂芳基，其在与W 1 的结合位置相对应的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐 这些化合物可用作器官或组织的纤维化抑制剂等药物。
• [EN] COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ ANTAGONISTE DE CRTH2
  申请人：OXAGEN LTD

  公开号：WO2009093029A1

  公开（公告）日：2009-07-30

  Compounds of general formula (I): wherein W is chloro or fluoro; Z is a group SO2R1; wherein R1 is -C3-C8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)POR2, and - O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -Ci-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  通式（I）的化合物：其中W是氯或氟；Z是一个SO2R1基团；其中R1是-C3-C8环烷基或杂环烷基，可选择地用来替代一个或多个卤素，-CN，-C1-C6烷基，-SOR3，-SO2R3，-SO2N(R2)2，-N(R2)2，-NR2C(O)R3，-CO2R2，-CONR2R3，-NO2，-OR2，-SR2，-O(CH2)POR2，和-O(CH2)pO(CH2)qOR2中的一个或多个取代基，其中每个R2独立地是氢，-C1-C6烷基，-C3-C8环烷基，芳基或杂芳基；每个R3独立地是-C1-C6烷基，-C3-C8环烷基，芳基或杂芳基；p和q分别独立地是1到3之间的整数；它们的药用盐，水合物，溶剂合物或前药在口服给药组合物中对治疗过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎非常有用。
• Compounds Having CRTH2 Antagonist Activity
  申请人：Armer Richard Edward

  公开号：US20090192195A1

  公开（公告）日：2009-07-30

  Compounds of general formula (I) wherein W is chloro or fluoro; Z is a group SO 2 R 1 ; wherein R 1 is —C 3 -C 8 cycloalkyl or heterocyclyl optionally substituted with one or more substituents chosen from halo, —CN, —C 1 -C 6 alkyl, —SOR 3 , —SO 2 R 3 , —SO 2 N(R 2 ) 2 , —N(R 2 ) 2 , —NR 2 C(O)R 3 , —CO 2 R 2 , —CONR 2 R 3 , —NO 2 , —OR 2 , —SR 2 , —O(CH 2 ) p OR 2 , and —O(CH 2 ) p —O—(CH 2 ) q OR 2 wherein each R 2 is independently hydrogen, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, aryl or heteroaryl; each R 3 is independently, —C 1 -C 6 alkyl, —C 3 -C 8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  通式（I）的化合物其中W是氯或氟；Z是一个SO2R1基团；其中R1是—C3-C8环烷基或杂环烷基，可选择地取代一个或多个卤素、—CN、—C1-C6烷基、—SOR3、—SO2R3、—SO2N(R2)2、—N(R2)2、—NR2C(O)R3、—CO2R2、—CONR2R3、—NO2、—OR2、—SR2、—O(CH2)pOR2和—O(CH2)p—O—(CH2)qOR2其中每个R2独立地是氢、—C1-C6烷基、—C3-C8环烷基、芳基或杂芳基；每个R3独立地是—C1-C6烷基、—C3-C8环烷基、芳基或杂芳基；p和q分别是1到3之间的整数；它们的药用盐、水合物、溶剂合物或前药在口服组合物中用于治疗过敏性疾病，如哮喘、过敏性鼻炎和特应性皮炎。
• SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I
  申请人：Fink Marc David

  公开号：US20070299112A1

  公开（公告）日：2007-12-27

  The present invention discloses and claims compounds of formula (I) and formula (II), as inhibitors of human casein kinase Iε and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) or formula (II) and a method for the preparation of compounds of formula (I) or formula (II) are also disclosed and claimed.

  本发明揭示和声明公式(I)和公式(II)的化合物，作为人类酪蛋白激酶Iε的抑制剂，并提供使用这些化合物治疗中枢神经系统疾病和紊乱，包括情绪障碍和睡眠障碍的方法。还揭示和声明了包含公式(I)或公式(II)化合物的药物组合物，以及制备公式(I)或公式(II)化合物的方法。